J
Jeremy A. Squire
Researcher at University of São Paulo
Publications - 349
Citations - 41173
Jeremy A. Squire is an academic researcher from University of São Paulo. The author has contributed to research in topics: Comparative genomic hybridization & Fluorescence in situ hybridization. The author has an hindex of 87, co-authored 344 publications receiving 38764 citations. Previous affiliations of Jeremy A. Squire include University of Toronto & Kingston General Hospital.
Papers
More filters
Journal ArticleDOI
Identification of human brain tumour initiating cells
Sheila K. Singh,Cynthia Hawkins,Ian D. Clarke,Jeremy A. Squire,Jane Bayani,Takuichiro Hide,R. Mark Henkelman,Michael D. Cusimano,Peter B. Dirks +8 more
TL;DR: The development of a xenograft assay that identified human brain tumour initiating cells that initiate tumours in vivo gives strong support for the CSC hypothesis as the basis for many solid tumours, and establishes a previously unidentified cellular target for more effective cancer therapies.
Journal Article
Identification of a Cancer Stem Cell in Human Brain Tumors
Sheila K. Singh,Ian D. Clarke,Mizuhiko Terasaki,Victoria E. Bonn,Cynthia Hawkins,Jeremy A. Squire,Peter B. Dirks +6 more
TL;DR: The identification and purification of a cancer stem cell from human brain tumors of different phenotypes that possesses a marked capacity for proliferation, self-renewal, and differentiation is reported.
Journal ArticleDOI
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao,Akira Sakurada,Jean-Claude Cutz,Jean-Claude Cutz,Chang-Qi Zhu,Chang-Qi Zhu,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Jeremy A. Squire,Ian A. J. Lorimer,Tong Zhang,Tong Zhang,Ni Liu,Ni Liu,Manijeh Daneshmand,Paula Marrano,Paula Marrano,Gilda da Cunha Santos,Gilda da Cunha Santos,Alain E. Lagarde,Frank C. Richardson,Lesley Seymour,Marlo Whitehead,Keyue Ding,Joseph L. Pater,Frances A. Shepherd,Frances A. Shepherd +27 more
TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
Journal ArticleDOI
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman,Philip T. Cagle,Mary Beth Beasley,Dhananjay Chitale,Sanja Dacic,Giuseppe Giaccone,Robert Brian Jenkins,David J. Kwiatkowski,Juan Sebastian Saldivar,Jeremy A. Squire,Erik Thunnissen,Marc Ladanyi +11 more
TL;DR: 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B), to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor in all patients with advanced-stage adenocarcinoma.
Journal ArticleDOI
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.
Steven M. Pollard,Koichi Yoshikawa,Ian D. Clarke,Davide Danovi,Stefan H. Stricker,Roslin Russell,Jane Bayani,Renee Head,Marco Lee,Mark Bernstein,Jeremy A. Squire,Austin Smith,Peter B. Dirks +12 more
TL;DR: Routine and efficient derivation of adherent cell lines from malignant glioma that display stem cell properties and initiate high-grade gliomas following xenotransplantation are demonstrated.